CT1812

A Randomized, Double-blind, Placebo-controlled, Phase 2, Six-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies

Galvin JE, Tolea MI, Hamby ME, et al. A Randomized, Double-blind, Placebo-controlled, Phase 2, Six-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies. Poster presented at: 2022 Clinical Trials on Alzheimer’s Disease Congress (CTAD); San Francisco, CA.

A Randomized, Double-blind, Placebo-controlled, Phase 2, Six-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies Read More »

CSF Proteomics Biomarker Analysis from the SPARC Clinical Trial: to Assess the Effect of the Sigma-2 Receptor (S2R) Modulator CT1812 in Alzheimer’s Disease Patients

Pandey K, Waybright L, Duong DM, et al. CSF Proteomics Biomarker Analysis from the SPARC Clinical Trial: to Assess the Effect of the Sigma-2 Receptor (S2R) Modulator CT1812 in Alzheimer’s Disease Patients. Oral presentation at: 2022 Alzheimer’s Association’s International Conference (AAIC); San Diego, CA.

CSF Proteomics Biomarker Analysis from the SPARC Clinical Trial: to Assess the Effect of the Sigma-2 Receptor (S2R) Modulator CT1812 in Alzheimer’s Disease Patients Read More »

Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812

Seyfried N, Waybright L, Duong D, et al. Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.

Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812 Read More »

Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF

Izzo NJ, LaBarbera KM, Yuede CM, et al. Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.

Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF Read More »

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

1 Comment

Pittsburgh, October 19, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease Read More »

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org